From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Reducing graft-vs-host disease in blood stem cell transplants

Last Updated: Tuesday, June 14, 2022

Analysis of phase 2 clinical trials suggests that depleting one type of T cell in donor stem cells could potentially reduce chronic GvHD without increasing cancer recurrence.

JAMA
Advertisement
News & Literature Highlights
Advertisement
Advertisement